肠促胰岛素在肥胖与非酒精性脂肪性肝病治疗中的未来
综述指出,胰高血糖素样肽-1受体(GLP-1R)激动剂已改变2型糖尿病治疗指南并改善结局;双受体激动剂替尔泊肽在改善HbA1c和体重方面显示更优疗效。基于双靶点和多靶点激动剂的多种化合物正被研究用于代谢性疾病,多器官靶点多靶点激动剂可能改变肥胖和非酒精性脂肪性肝病(NAFLD)的自然史。
要点
- GLP-1R激动剂已改变2型糖尿病治疗指南并改善结局。
- 替尔泊肽在改善HbA1c和体重方面显示更优疗效。
- 多器官靶点多靶点激动剂可能改变肥胖和NAFLD的自然史。
核心结论
- 利用肠促胰岛素治疗肥胖及可能的NAFLD已取得关键科学进展。
- 多器官靶点多靶点激动剂的开发可能改变这些疾病的自然史。
研究设计与样本
- 综述,未报告检索范围。
主要发现
- GLP-1R激动剂已改变当前指南并改善2型糖尿病患者的结局。
- 双受体激动剂替尔泊肽在改善2型糖尿病患者HbA1c和体重方面显示更优疗效。
- 多种基于双靶点和多靶点激动剂的化合物正被研究用于代谢性疾病治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the last few decades, glucagon-like peptide-1 receptor (GLP-1R) agonists have changed current guidelines and improved outcomes for individuals with type 2 diabetes. However, the dual glucose-dependent insulinotropic polypeptide receptor (GIPR)/GLP-1R agonist, tirzepatide, has demonstrated superior efficacy regarding improvements in HbA1c and body weight in people with type 2 diabetes. This has led to increasing scientific interest in incretin hormones and incretin interactions, and several compounds based on dual- and multi-agonists are now being investigated for the treatment of metabolic diseases. Herein, we highlight the key scientific advances in utilising incretins for the treatment of obesity and, potentially, non-alcoholic fatty liver disease (NAFLD). The development of multi-agonists with multi-organ targets may alter the natural history of these diseases.
引用
- Andreasen CR, Andersen A, Vilsbøll T, et al. The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. Diabetologia. 2023. PMID: 37498367. doi:10.1007/s00125-023-05966-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。